Table 3.
Anti-inflammatory treatments, eyes of patients with intermediate uveitis, Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
| Cox model of Cataract by Visual Acuity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Cataract | Crude | Adjusted* | ||||||
| Total | No | Yes | Hazard Ratio (95% Cl) | p | Hazard Ratio (95% Cl) | p | ||
| Cumulative Periocular Corticosteroid Injections** | Never | 2062 (94%) | 1828 (89%) | 234 (11%) | Ref | 0.003 | Ref | 0.049 |
| 1 injection | 128 (6%) | 104 (81%) | 24 (19%) | 1.50 (1.04, 2.19) | 1.47 (0.98, 2.20) | |||
| 2–3 injections*** | 1.43 (0.88, 2.32) | 1.42 (0.86, 2.33) | ||||||
| ≥4 injections*** | 2.61 (1.45, 4.70) | 2.01 (1.05, 3.85) | ||||||
| Topical Corticosteroids** | None | 1327 (61%) | 1181 (89%) | 146 (11%) | Ref | <0.001 | Ref | 0.01 |
| 1 drop | 52 (2%) | 45 (87%) | 7 (13%) | 1.10 (0.45, 2.68) | 0.79 (0.34, 1.82) | |||
| ≥2 drops | 811 (37%) | 706 (87%) | 105 (13%) | 2.07 (1.54, 2.78) | 1.55 (1.13, 2.12) | |||
| Oral Corticosteroids** | None | 1834 (84%) | 1633 (89%) | 201 (11%) | Ref | 0.003 | Ref | 0.02 |
| >0 – ≤7.5 mg/day | 45 (2%) | 43 (96%) | 2 (4%) | 0.65 (0.30, 1.40) | 0.49 (0.24, 0.99) | |||
| >7.5 mg/day | 311 (14%) | 256 (82%) | 55 (18%) | 1.72 (1.22, 2.45) | 1.32 (0.92, 1.90) | |||
| Any IMT** | No | 1975 (90%) | 1746 (88%) | 229 (12%) | Ref | <0.001 | Ref | <0.001 |
| Yes | 215 (10%) | 186 (87%) | 29 (13%) | 1.90 (1.42, 2.55) | 1.67 (1.24, 2.25) |
*
Adjusted for PPV, posterior synechia, epiretinal membrane, any IMTs, cumulative periocular steroid injections, topical steroids, and oral steroids
**
Time-updated
***
No eyes met criteria for inclusion in these categories at time of enrollment, but were included as appropriate with time-updated data
CI = confidence interval; IMT = immunomodulatory therapy; PPV = pars plana vitrectomy; Ref = reference value